Literature DB >> 19089423

A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.

Nancy Lynn Booth1, Thomas J Sayers, Alan D Brooks, Cheryl L Thomas, Kristen Jacobsen, Ekaterina I Goncharova, James B McMahon, Curtis J Henrich.   

Abstract

We have developed a high-throughput screen (HTS) to search for novel molecules that can synergize with TRAIL, thus promoting apoptosis of ACHN renal tumor cells in a combinatorial fashion. The HTS detects synthetic compounds and pure natural products that can pre-sensitize the cancer cells to TRAIL-mediated apoptosis, yet have limited toxicity on their own. We have taken into account the individual effects of the single agents, versus the combination, and have identified hits that are synergistic, synergistic-toxic, or additive when combined with TRAIL in promoting tumor cell death. Preliminary mechanistic studies indicate that a subset of the synergistic TRAIL sensitizers act very rapidly to promote cleavage and activation of caspase-8 following TRAIL binding. Caspase-8 is an apical enzyme that initiates programmed cell death via the extrinsic apoptotic pathway. Thus, these TRAIL sensitizers may potentially reduce resistance of tumor cells to TRAIL-mediated apoptosis. Two representative sensitizers were found to increase levels of p53 but did not inhibit the proteasome, suggesting that early DNA damage-sensing pathways may be involved in their mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19089423      PMCID: PMC3168559          DOI: 10.1007/s00262-008-0637-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  77 in total

Review 1.  The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives.

Authors:  Felipe Lombó; Nuria Menéndez; José A Salas; Carmen Méndez
Journal:  Appl Microbiol Biotechnol       Date:  2006-09-30       Impact factor: 4.813

Review 2.  The clinical trail of TRAIL.

Authors:  E W Duiker; C H Mom; S de Jong; P H B Willemse; J A Gietema; A G J van der Zee; E G E de Vries
Journal:  Eur J Cancer       Date:  2006-08-01       Impact factor: 9.162

Review 3.  Shared pathways: death receptors and cytotoxic drugs in cancer therapy.

Authors:  I Peták; J A Houghton
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

4.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Authors:  J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

Review 5.  Targeting death receptors in bladder, prostate and renal cancer.

Authors:  Hugh F O'Kane; Chris J Watson; Samuel R Johnston; Istvan Petak; R William G Watson; Kate E Williamson
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

6.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Caspase-8-mediated BID cleavage and release of mitochondrial cytochrome c during Nomega-hydroxy-L-arginine-induced apoptosis in MDA-MB-468 cells. Antagonistic effects of L-ornithine.

Authors:  Rajan Singh; Shehla Pervin; Gautam Chaudhuri
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

Review 9.  TRAIL-receptor antibodies as a potential cancer treatment.

Authors:  Donald J Buchsbaum; Andres Forero-Torres; Albert F LoBuglio
Journal:  Future Oncol       Date:  2007-08       Impact factor: 3.404

10.  Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

Authors:  Ruth Plummer; Gerhardt Attard; Simon Pacey; Louise Li; Albiruni Razak; Rebecca Perrett; Mary Barrett; Ian Judson; Stan Kaye; Norma Lynn Fox; Wendy Halpern; Alfred Corey; Hilary Calvert; Johann de Bono
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

View more
  19 in total

1.  Microwave-based reaction screening: tandem retro-Diels-Alder/Diels-Alder cycloadditions of o-quinol dimers.

Authors:  Suwei Dong; Katharine J Cahill; Moon-Il Kang; Nancy H Colburn; Curtis J Henrich; Jennifer A Wilson; John A Beutler; Richard P Johnson; John A Porco
Journal:  J Org Chem       Date:  2011-10-07       Impact factor: 4.354

2.  Synergistic TRAIL sensitizers from Barleria alluaudii and Diospyros maritima.

Authors:  Emily L Whitson; Han Sun; Cheryl L Thomas; Curtis J Henrich; Thomas J Sayers; James B McMahon; Christian Griesinger; Tawnya C McKee
Journal:  J Nat Prod       Date:  2012-02-07       Impact factor: 4.050

3.  Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth.

Authors:  Atsushi Kawabata; Abdulgader Baoum; Naomi Ohta; Stephanie Jacquez; Gwi-Moon Seo; Cory Berkland; Masaaki Tamura
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

4.  Isolation, structural elucidation, and absolute stereochemistry of enigmazole A, a cytotoxic phosphomacrolide from the Papua New Guinea marine sponge Cinachyrella enigmatica.

Authors:  Naoya Oku; Kentaro Takada; Richard W Fuller; Jennifer A Wilson; Megan L Peach; Lewis K Pannell; James B McMahon; Kirk R Gustafson
Journal:  J Am Chem Soc       Date:  2010-08-04       Impact factor: 15.419

5.  US National Cancer Institute-China Collaborative Studies on Chinese Medicine and Cancer.

Authors:  Libin Jia; Hongsheng Lin; Joost Oppenheim; O M Zack Howard; Jie Li; Huiting Fan; Zhizheng Zhao; William Farrar; Ying Zhang; Nancy Colburn; Matthew R Young; Weidong Li; David Newman; Barry R O'Keefe; John Beutler; Jikai Liu; Xiaojiang Hao; Xiaosheng Yang; Tengfei Ji; Jeffrey D White
Journal:  J Natl Cancer Inst Monogr       Date:  2017-11-01

6.  Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.

Authors:  Curtis J Henrich; Cheryl L Thomas; Alan D Brooks; Nancy Lynn Booth; Evan M Lowery; Richard J Pompei; James B McMahon; Thomas J Sayers
Journal:  Apoptosis       Date:  2012-01       Impact factor: 4.677

7.  Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.

Authors:  T Bagci-Onder; A Agarwal; D Flusberg; S Wanningen; P Sorger; K Shah
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 9.867

8.  Sharkquinone, a new ana-quinonoid tetracene derivative from marine-derived Streptomyces sp. EGY1 with TRAIL resistance-overcoming activity.

Authors:  Mohamed S Abdelfattah; Mohammed I Y Elmallah; Adal A Mohamed; Masami Ishibashi
Journal:  J Nat Med       Date:  2017-04-04       Impact factor: 2.343

9.  Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme.

Authors:  Filiz Senbabaoglu; Ahmet Cingoz; Ezgi Kaya; Selena Kazancioglu; Nathan A Lack; Ceyda Acilan; Tugba Bagci-Onder
Journal:  Cancer Biol Ther       Date:  2016-03-30       Impact factor: 4.742

Review 10.  Matching the power of high throughput screening to the chemical diversity of natural products.

Authors:  Curtis J Henrich; John A Beutler
Journal:  Nat Prod Rep       Date:  2013-08-08       Impact factor: 13.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.